{"doc_id": "si-2023-0451-reg-1", "parent_doc_id": "si-2023-0451", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 451 of 2023", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2023, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) (No. 6) Regulations 2023. \n\n(2) The collective citation “the Medicinal Products (Prescription and Control \n\nof Supply) Regulations 2003 to 2023” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 6) regulation 2023 (2) collective citation medicinal product (prescription control supply) regulation 2003 2023 includes regulation", "start_char": 618, "end_char": 908, "source_path": "downloads\\2023\\2023_0451.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f2fa6cd5e955b35b4fb7318af0e43d8023c44ce48c153bec12959c6b5d855b85", "cross_refs": []}
{"doc_id": "si-2023-0451-reg-2", "parent_doc_id": "si-2023-0451", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 451 of 2023", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2023, "heading": "In these Regulations “Principal Regulations” means the Medicinal", "text_raw": "2. \n\nIn these Regulations “Principal Regulations” means the Medicinal \nProducts (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of \n2003).", "text_norm": "2 regulation principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003)", "start_char": 908, "end_char": 1069, "source_path": "downloads\\2023\\2023_0451.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f2fa6cd5e955b35b4fb7318af0e43d8023c44ce48c153bec12959c6b5d855b85", "cross_refs": []}
{"doc_id": "si-2023-0451-reg-3", "parent_doc_id": "si-2023-0451", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 451 of 2023", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2023, "heading": "3. The Eighth Schedule (as amended by Regulation 8 of the Medicinal", "text_raw": "3. The Eighth Schedule (as amended by Regulation 8 of the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) (No. 4) Regulations \n2023 (S.I. No. 284 of 2023)) to the Principal Regulations is amended by inserting \nthe following entry: \n\n“ \n\nMedicinal \nProduct \n\nRoute of \nadministration \n\nForm and \npresentation \nof product \nadministered \n\nIndication for \nwhich the \nmedicinal \nproduct may \nbe \nadministered \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministration \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nColumn 6 \n\nCOMIRNATY \nOmicron \nXBB.1.5 \n30 mcg/dose \n\nDispersion \nfor injection \n\nIntramuscular \ninjection \n\nActive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV-2 \nin individuals \n12 years of \nage and older \n\nAny suitable \nand appropriate \nplace, having \nregard to public \nconvenience and \nthe need to \nprotect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand/or \nrelevant \nnational \nguidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee \n\nNotice of the making of this Statutory Instrument was published in \n\"Iris Oifigiúil\" of 19th September, 2023. \n\n \n \n \n \n \n \n \n\fCOMIRNATY \nOmicron \nXBB.1.5 \n10 mcg/dose \n\nConcentrate \nfor \ndispersion \nfor injection \n\nIntramuscular \ninjection \n\nCOMIRNATY \nOmicron \nXBB.1.5 \n10 mcg/dose \n\nDispersion \nfor injection \n\nIntramuscular \ninjection \n\n[451] 3 \n\nAny suitable \nand appropriate \nplace, having \nregard to public \nconvenience and \nthe need to \nprotect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nAny suitable \nand appropriate \nplace, having \nregard to public \nconvenience and \nthe need to \nprotect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nActive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV-2 \nin children \naged 5 to 11 \nyears. \n\nActive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV-2 \nin children \naged 5 to 11 \nyears. \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand/or \nrelevant \nnational \nguidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand/or \nrelevant \nnational \nguidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee \n\n”.", "text_norm": "3 eighth schedule (as amended regulation 8 medicinal product (prescription control supply) (amendment) (no 4) regulation 2023 (s.i no 284 2023)) principal regulation amended inserting following entry medicinal product route administration form presentation product administered indication medicinal product may administered dosage condition administration place administration column 1 column 2 column 3 column 4 column 5 column 6 comirnaty omicron xbb.1.5 30 mcg dose dispersion injection intramuscular injection active immunisation prevent covid-19 caused sars-cov-2 individual 12 year age older suitable appropriate place regard public convenience need protect health safety public safely administer product accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee notice making statutory instrument published iris oifigiuil 19th september 2023 comirnaty omicron xbb.1.5 10 mcg dose concentrate dispersion injection intramuscular injection comirnaty omicron xbb.1.5 10 mcg dose dispersion injection intramuscular injection 451 3 suitable appropriate place regard public convenience need protect health safety public safely administer product suitable appropriate place regard public convenience need protect health safety public safely administer product active immunisation prevent covid-19 caused sars-cov-2 child aged 5 11 year active immunisation prevent covid-19 caused sars-cov-2 child aged 5 11 year accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee", "start_char": 1069, "end_char": 3530, "source_path": "downloads\\2023\\2023_0451.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f2fa6cd5e955b35b4fb7318af0e43d8023c44ce48c153bec12959c6b5d855b85", "cross_refs": []}
{"doc_id": "si-2023-0451-reg-4", "parent_doc_id": "si-2023-0451", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 451 of 2023", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2023, "heading": "4. The Twelfth Schedule (as amended by Regulation 6 of the Medicinal", "text_raw": "4. The Twelfth Schedule (as amended by Regulation 6 of the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) (No. 5) Regulations \n2023 (S.I. No. 422 of 2023)) to the Principal Regulations is amended by inserting \nthe following entry: \n\n“ \n\nMedicinal \nproduct \n\nForm and \npresentation \nof product \nadministered \n\nRoute of \nadministration \n\nIndication for \nwhich the \nmedicinal product \nmay be \nadministered \n\nDosage and conditions \nof administration \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nCOMIRNATY \nOmicron \nXBB.1.5 \n30 mcg/dose \n\nDispersion \nfor injection \n\nIntramuscular \ninjection \n\nActive \nimmunisation to \nprevent COVID-19 \ncaused by SARSCoV-2 in \nindividuals 12 years \nof age and older. \n\nIn accordance with the \nsummary of product \ncharacteristics of the \nproduct administered \nand/or relevant national \nguidelines issued by the \nNational Immunisation \nAdvisory Committee. \n\n \n \n \n\f4 [451] \n\nCOMIRNATY \nOmicron \nXBB.1.5 \n10 mcg/dose \n\nConcentrate \nfor dispersion \nfor injection \n\nIntramuscular \ninjection \n\nCOMIRNATY \nOmicron \nXBB.1.5 \n10 mcg/dose \n\nDispersion \nfor injection \n\nIntramuscular \ninjection \n\n”. \n\nActive \nimmunisation to \nprevent COVID-19 \ncaused by SARSCoV-2 in children \naged 5 to 11 years. \n\nActive \nimmunisation to \nprevent COVID-19 \ncaused by SARSCoV-2 in children \naged 5 to 11 years. \n\nIn accordance with the \nsummary of product \ncharacteristics of the \nproduct administered \nand/or relevant national \nguidelines issued by the \nNational Immunisation \nAdvisory Committee \n\nIn accordance with the \nsummary of product \ncharacteristics of the \nproduct administered \nand/or relevant national \nguidelines issued by the \nNational Immunisation \nAdvisory Committee \n\nGIVEN under my Official Seal, \n\n14 September, 2023. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[451] 5", "text_norm": "4 twelfth schedule (as amended regulation 6 medicinal product (prescription control supply) (amendment) (no 5) regulation 2023 (s.i no 422 2023)) principal regulation amended inserting following entry medicinal product form presentation product administered route administration indication medicinal product may administered dosage condition administration column 1 column 2 column 3 column 4 column 5 comirnaty omicron xbb.1.5 30 mcg dose dispersion injection intramuscular injection active immunisation prevent covid-19 caused sarscov-2 individual 12 year age older accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee 4 451 comirnaty omicron xbb.1.5 10 mcg dose concentrate dispersion injection intramuscular injection comirnaty omicron xbb.1.5 10 mcg dose dispersion injection intramuscular injection  active immunisation prevent covid-19 caused sarscov-2 child aged 5 11 year active immunisation prevent covid-19 caused sarscov-2 child aged 5 11 year accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee given official seal 14 september 2023 stephen donnelly minister health 451 5", "start_char": 3530, "end_char": 5385, "source_path": "downloads\\2023\\2023_0451.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f2fa6cd5e955b35b4fb7318af0e43d8023c44ce48c153bec12959c6b5d855b85", "cross_refs": []}
{"doc_id": "si-2023-0451-explanatory-note", "parent_doc_id": "si-2023-0451", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 451 of 2023", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2023, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to update the relevant schedules in relation \nto the COVID-19 vaccines to include the COMIRNATY Omicron XBB.1.5 \nvaccine. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 6) Regulations 2023. \n\n \n \n \n \n \n \n \n\f6 [451] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-503) 75. 9/23. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation update relevant schedule relation covid-19 vaccine include comirnaty omicron xbb.1.5 vaccine regulation may cited medicinal product (prescription control supply) (amendment) (no 6) regulation 2023 6 451 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-503) 75 9 23 propylon", "start_char": 5385, "end_char": 6408, "source_path": "downloads\\2023\\2023_0451.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f2fa6cd5e955b35b4fb7318af0e43d8023c44ce48c153bec12959c6b5d855b85", "cross_refs": []}
